ArticleFrontiers in cellular and infection microbiology2026
Two decades of mucormycosis: molecular epidemiology and antifungal susceptibility trends in Türkiye.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucormycosis is a life-threatening invasive fungal infection that mainly affects individuals with weakened immune systems. Despite its clinical importance, data from Türkiye on the epidemiology and antifungal susceptibility of fungi belonging to the order Mucorales are scarce. This study aimed to describe the clinical, epidemiological, and mycological features of mucormycosis over a twenty-year period at a tertiary care hospital. Methods: All cases of mucormycosis diagnosed between 2003 and 2022 at Bursa Uludağ University Hospital were retrospectively evaluated. Cases were classified as proven or probable according to international definitions. Molecular identification was based on internal transcribed spacer sequencing. Large subunit ribosomal DNA region sequencing and whole-genome sequencing were performed when necessary. Antifungal susceptibility testing for amphotericin B and posaconazole was performed according to the Clinical and Laboratory Standards Institute M38 guideline. Statistical analyses included chi-square, Fisher's exact, Spearman's correlation, and Wilcoxon signed-rank tests. Results: A total of 187 cases were identified, comprising 134 proven and 53 probable. Rhino-cerebral infection was the most frequent form, followed by pulmonary disease. Hematologic malignancy was the most common underlying condition, and mortality was 52.9 percent. Molecular identification was achieved for 99 isolates, with Conclusion: This single-center study provides the most comprehensive data on mucormycosis in Türkiye and highlights the importance of molecular surveillance to guide antifungal therapy and monitor regional variations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.